



# NOTES

## INFLAMMATORY ARTHRITIS

### GENERALLY, WHAT IS IT?

#### PATHOLOGY & CAUSES

- Musculoskeletal disease subset; known immune component underlying disease
- Underlying trigger/cause not always understood

#### SIGNS & SYMPTOMS

- Painful, warm, stiff joints
- Variable extra-articular symptoms

#### DIAGNOSIS

##### LAB RESULTS

##### Synovial fluid analysis

- Cloudy yellow appearance
- White blood cell count (WBC) > 5,000
- Polymorphonuclear neutrophils (PMNs) < 25%

#### TREATMENT

##### MEDICATION

##### Anti-inflammatory medication

- Common NSAIDs
- Immunologically-targeted therapy
  - Anti-cytokine therapy (e.g. adalimumab)

## ANKYLOSING SPONDYLITIS

[osms.it/ankylosing-spondylitis](https://osms.it/ankylosing-spondylitis)

#### PATHOLOGY & CAUSES

- **Group:** seronegative spondyloarthritis
- **Characteristics:** articular cartilage destruction, bony joint fusion (ankylosis) → primarily spine, sacroiliac joints
- AKA rheumatoid spondylitis, Marie-Strümpell disease
- Autoimmune self-reactivity believed to underlie pathophysiology
  - Strong HLA-B27 association (MHC I serotype; positive in 90% of affected individuals)

- Relative risk for HLA-B27 individuals: 100-200x
- IL-23 receptor gene also implicated
- Abnormal IL-23 cytokine regulation → naive CD4+ T cell → self-reactive Th17 cells
- Associated with Crohn's disease, ulcerative colitis

#### RISK FACTORS

- Biological sex
  - 3x ↑ individuals who are biologically male

## COMPLICATIONS

- Aortic regurgitation
  - Aortic aneurysm → aortic valve annulus stretched → regurgitation
- Uveitis
- Enthesitis (tendinous insertion inflammation)
- Dactylitis (“sausage fingers”)
- Decreased pulmonary function
- Thoracic-rib articulation spondylosis → ↓ chest wall expansion across respiratory cycle
- Secondary amyloidosis

## SIGNS & SYMPTOMS

- Symptoms develop teens-20s
  - Lower back pain, spinal immobility
- Peripheral large joints (hips, knees, shoulders) involved in 1/3 of individuals
- Morning stiffness; improves throughout day, with exercise
- Untreated disease → extenuated kyphosis of spine

## DIAGNOSIS

### DIAGNOSTIC IMAGING

#### Lumbar spine radiograph

- Diagnostic → sacroileitis
- Progression of early findings
  - Subchondral erosions (pseudo-widening effect on X-ray) → sclerosis → sacroiliac joint fusion
- Late findings (10+ years of disease)
  - “**Bamboo spine**”: prominent syndesmophytes (bony growth inside ligaments), diffuse calcification of paraspinal ligaments, spinal osteoporosis

### LAB RESULTS

- ↑ erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) suggestive, not diagnostic
- ⊖ Rheumatoid factor (RF)



**Figure 111.1** An X-ray image of demonstrating bamboo spine and the dagger sign in an individual with ankylosing spondylitis.

### OTHER DIAGNOSTICS

- Family history
- Physical examination
  - ↓ Spine flexion/extension and ↓ lateral range of motion

## TREATMENT

### MEDICATIONS

- NSAIDs (maximum daily dosing recommended)
  - First line for pain, stiffness
- TNF-alpha inhibitors
  - **Etanercept**: fusion protein (IgG1 Fc region, TNF alpha receptor); intercepts circulating TNF-alpha, competes with body's TNF alpha receptors
  - **Infliximab, adalimumab, certolizumab**: anti-TNF alpha monoclonal antibodies
  - **Sulfasalazine**: if TNF-alpha therapy ineffective; recommended for peripheral joint disease



**Figure 111.2** The skeleton of an individual with ankylosing spondylitis. The lumbar and cervical spine have ossified completely and become fused.

## OTHER INTERVENTIONS

- Exercise therapy
  - Home exercise therapy/formal physical therapy regimens
- Tobacco use cessation
- Heat, ice packs

# GOUT

[osms.it/gout](https://osms.it/gout)

## PATHOLOGY & CAUSES

- Episodic, arthritic disorder
- **Monosodium urate crystallization** in, around joint spaces; when left untreated, can manifest as **tophi** in **chronic** arthritic disorder
- **Monosodium urate (MSU)**: purine and pyrimidine (nitrogen containing heterocycles; DNA components) → primary sources of uric acid; released when cells broken down
  - Limited solubility in plasma (only 6.8mg/dL)
  - Poorer solubility in joint space → lower temperature, synovial fluid composition favor precipitation
- Sources of nidus (precipitates crystals) include collagen fibers, chondroitin sulfate, proteoglycans, cartilage fragments
- Physiologic pH of 7.4 → uric acid loses cation, adds  $\text{Na}^+$  → MSU crystals
- **Damage pathway**: MSU precipitate into joints → complement cascade activated, cytokines produced → leukocyte recruitment → macrophages phagocytose MSU → inflammasome activates caspase-1 → produce IL-1 and other proinflammatory cytokines → ↑↑↑ leukocyte recruitment, cytokine production
- Classification
  - 90% primary/idiopathic
  - 10% secondary

## CAUSES


- ↑ production of uric acid, purines (most common)
- Diet high in red meat, shellfish, anchovies, organ meat
- ↑ cell turnover
- Cancer treatment → tumor lysis syndrome
- Polycythemia vera (5–10% develop gout)
- Lesch-Nyhan syndrome
  - Hypoxanthine guanine phosphoribosyl transferase (HGPRT) deficiency interrupts purine salvage pathway → ↑ degradation of purines → ↑ uric acid production
- Dehydration, alcoholic beverage consumption → ↓ clearance of uric acid
- Chronic kidney disease

## RISK FACTORS

- Age
  - 20–30+ years of hyperuricemia → ↑ risk
- Biological sex (↑ individuals who are biologically male)
- Genetic
  - HGPRT (X-linked); URAT1, GLUT9 (both involved in urate transport/homeostasis)
- Heavy alcohol consumption
- Obesity
- Drugs that ↓ urate excretion/↑ production (e.g. thiazides, aspirin)
- Glucose metabolism abnormalities (e.g. diabetes mellitus)
- Chronic lead toxicity → saturnine gout
  - Most common risk factor in U.S. is moonshine consumption → lead-lined stills



**Figure 11.4** Gout of the great toe presenting as erythema of the overlying skin.



**Figure 11.3** Urate crystals will display negative birefringence on polarised light microscopy.

## COMPLICATIONS

- Gravel/stone passage → renal colic
- Renal failure → death in 20% individuals with chronic gout
- ↓ quality of life, generally not lifespan

## SIGNS & SYMPTOMS

### Acute, episodic arthritis

- Nocturnal onset
  - Awakening with complaints, e.g. “feeling like toe on fire”
- Most severe pain remits within first hours; pain can last days–weeks
- Painful, warm, erythematous, and swollen joint → ↓ range of motion → disability

### First episode

- Commonly monoarticular; 50% of cases include first metatarsal joint (aka podagra)
- Asymptomatic period months–years → subsequent episodes (mono- or polyarticular)
  - 90% of other joints involved, progressively (ankle > heels > knees > wrists > fingers > elbows)
  - ↑ episodes, polyarticular effects without treatment

### Chronic disease (tophaceous gout)

- On average, around 12 years after initial attack
- MSU deposition (joint spaces/affected cartilage)
- Painless, pedunculated mass; palpitation may discolor overlying skin
- Joint's range of motion sometimes limited
- Kidney complications take one of two forms
  - Symptoms of colicky flank pain, hematuria → uric acid nephrolithiasis
  - ↓ urine output, difficulty voiding → urate nephropathy

## DIAGNOSIS

### DIAGNOSTIC IMAGING

#### Radiographic/ultrasound/CT scan

- Joint destruction, bony erosions (rarely present on the first acute episode)
- Imaging findings become more likely with disease duration

#### X-ray

- Radiolucent uric acid nephrolithiasis

### LAB RESULTS

#### Synovial fluid analysis

- MSUs in context of acute, arthritic episodes

#### Polarized light microscope

- Long, slender **needle-shaped crystals** in synovial fluid, neutrophil cytoplasm
  - Negatively birefringent; yellow under parallel light, blue under perpendicular light

### OTHER DIAGNOSTICS

- Histological analysis of chronic tophaceous arthritis
  - Large aggregations of MSU surrounded by inflammatory reaction of foreign body giant cells
  - Hyperplastic, fibrotic, thickened synovium → pannus formation → destruction of underlying cartilage, juxta-articular bony erosions



**Figure 111.5** An X-ray image of the foot showing destruction of the first metatarsophalangeal joint by arthritis secondary to gout. There is an overlying gouty tophus.

- Histological analysis of gouty nephropathy
  - MSU (with/without tophi) deposits in medullary interstitium/tubules

## TREATMENT

### MEDICATIONS

#### Acute flare therapy

- Anti-inflammatory treatment ASAP within acute flare → rapid, complete resolution faster
- **Glucocorticoids** (oral and/or intra-articular injections)
- **NSAIDs** (i.e. naproxen, indomethacin)
- **Colchicine** (inhibits leukocyte migration)
- Biologic agents (IL-1 inhibitors)


**Management and prevention**

- Limit medications that alter urate balance (e.g. thiazides, aspirin)
- Initiate medications that ↓ uric acid levels
- **Xanthine oxidase (XO) inhibitors** (allopurinol, febuxostat)
  - **Mechanism of action:** directly inhibits enzyme → urate production, stimulates purine base reutilization → ↓ ↓ ↓ urate concentration
- Uricosuric medications (probenecid)
  - ↑ urate excretion at kidney
- Uricase medications (rasburicase)
  - Mimic enzyme that catalyzes urate conversion → allantoin (more soluble purine degradation product); enzyme absent in humans

**OTHER INTERVENTIONS**

- Benefit largely due to ↓ development/worsening of obesity, cardiovascular disease, diabetes mellitus

- Diet modification
  - Limit/avoid soda, red meat, seafood
- Alcohol moderation
- ↑ physical activity



**Figure 111.6** The histological appearance of a gouty tophus. There is a large aggregate of urate crystals which is associated with granulomatous inflammation.

# JUVENILE IDIOPATHIC ARTHRITIS

[osms.it/juvenile-idiopathic-arthritis](https://osms.it/juvenile-idiopathic-arthritis)

**PATHOLOGY & CAUSES**

- Arthritic symptoms of unknown etiology; present < 16 years old for ≥ six weeks
- Unknown pathophysiology; appears related to TH1 and TH17 cells → cell mediators
  - IL-1, IL-17, TNF-gamma

**RISK FACTORS**

- HLA and PTPN22 variants

**COMPLICATIONS**

- 10% develop disability in adulthood

**SIGNS & SYMPTOMS**

- Arthritis
  - Oligo- or polyarticular involvement; large joints affected > small
- Rheumatoid nodules, factor usually absent

**DIAGNOSIS****LAB RESULTS**

- Antinuclear antibodies may be ⊕ or ⊖

**TREATMENT**

- Similar to rheumatoid arthritis
- Some success with IL-6 R antibody biologic disease-modifying antirheumatic drug (DMARD)

# PSEUDOGOUT

osms.it/pseudogout

## PATHOLOGY & CAUSES

- Calcium pyrophosphate (CPP) crystal depositions in articular cartilage
- AKA chondrocalcinosis
- Unlike gout, hyperuricemia
  - No known direct substance concentration → ↑ crystal formation
- Pathway of joint inflammation, destruction similar to gout
  - Articular cartilage proteoglycans degraded, serve as nidus for crystal formation around chondrocytes
  - CPP crystals precipitate around chondrocytes → complement cascade activated, cytokines produced → leukocyte recruitment → macrophages phagocytose MSU (inflammasome activates caspase-1) → produce IL-1, other proinflammatory cytokines → further leukocyte recruitment, cytokine production

## CAUSES

- Sporadic (idiopathic)
- Hereditary
  - Autosomal dominant version → early manifestation, more severe symptoms
  - Also associated with osteoarthritis
  - Mutations in pyrophosphate transport channel
- Secondary to previous joint damage, hyperparathyroidism, hemochromatosis, hypothyroidism, ochronosis, diabetes

## RISK FACTORS

- Age
  - Usually affects individuals > 50 years; by > 85 years → 30–60% prevalence
- ↓ magnesium levels

## COMPLICATIONS

- Significant joint damage
  - ≤ 50% of individuals

## SIGNS & SYMPTOMS

- Episodic joint pain
  - Knee most commonly affected; followed by wrists → elbows → shoulders → ankles
- Duration of several days–weeks
- Oligo- or polyarticular
- Frequently asymptomatic

## DIAGNOSIS

### OTHER DIAGNOSTICS

#### Histological analysis

- Gross
  - Chalky, white, friable
- Microscopic
  - Aggregates stain as blue/purple, oval
- Crystals
  - Rhomboid, ⊕ birefringent
- Crystallization first develops in articular cartilage, menisci, intervertebral discs

#### Physical examination

- Acutely painful, inflamed joint; commonly knee

## TREATMENT

### MEDICATIONS

#### Acute flares

- NSAIDs
- Colchicine
- Glucocorticoids

#### Management and prevention

- Colchicine



**Figure 111.7** A calcium pyrophosphate crystal in joint fluid aspirated from the knee of an individual with pseudogout.

### OTHER INTERVENTIONS

- Treat underlying disorder (if known)
- Symptomatic therapy similar to gout treatment

## GOUT VS. PSEUDOGOUT

	GOUT	PSEUDOGOUT
<b>CRYSTALS</b>	Monosodium urate (MSU)	Calcium pyrophosphate (CPP)
<b>CRYSTAL HISTOLOGY</b>	Needle-shaped; $\ominus$ birefringent	Rhomboid; $\oplus$ birefringent
<b>AGE OF ONSET (YEARS)</b>	May be young, largely RF*-dependent	50+
<b>MOST COMMONLY AFFECTED JOINT</b>	1st MTP* joint	Knee

\*RF - risk factor, MTP - metatarsophalangeal joint

# PSORIATIC ARTHRITIS

osms.it/psoriatic-arthritis

## PATHOLOGY & CAUSES

- **Group:** seronegative spondyloarthritides
- **Associated with psoriasis**
- Affects peripheral, axial joints; ligaments, tendons (entheses)
- Abnormal T cell response to unknown culprit antigen
  - $T_H1$ ,  $T_H17$  cells thought responsible → stimulate activated  $CD8^+$  T cells → cytokine, growth factor environment change/destroy local tissue
  - Implicated synovial cell mediators: IL-1, IL-6, TNF-alpha, IL-8
  - Synovial fibroblasts interact with immune response → secreting IL-1beta, IL-6, and platelet-derived growth factors (PDGF)
  - Affected synovia marked with increased vascularity → ↑ leukocytic entryways

## TYPES

- **Mild:** one joint involved/responds to NSAIDs
- **Moderate-severe:** NSAID-resistant
- **Severe:** polyarticular, erosive; functional limitation

## CAUSES

- Local trauma induces dysregulated immune response → local tissue destruction
  - AKA Koebner phenomenon
- 10% of psoriatic individuals develop arthritis symptoms

## RISK FACTORS

- HLA-B27
- HLA-Cw6
- Obesity
- Associated diseases
  - Myopathy, enteropathy, AIDS
- Age: 30-50 years old

## SIGNS & SYMPTOMS

- Predominantly peripheral arthritis of hands, feet
- Distal interphalangeal (DIP) joint first affected, asymmetrically distributed in > 50% of individuals
- Sacroiliac joint affected in 20% of individuals
- Degree of joint involvement may be mild/progress → severe, disfiguring disease as in rheumatoid arthritis (RA)



**Figure 111.8** The feet of an individual with psoriatic arthritis. There is inflammation of the ankle and the interphalangeal joints as well as psoriatic nail changes.

## DIAGNOSIS

### DIAGNOSTIC IMAGING

- Characteristic “pencil-in-cup” malformation at DIP joint

## OTHER DIAGNOSTICS

### Histological analysis

- Similar to RA, but symptoms not as severe, remissions more frequent, joint destruction less frequent

### History

- 40% of affected individuals have first-degree relative with psoriatic arthritis

### Physical examination

- Integument examination consistent with psoriasis
- Papules, plaques with silver scales on extensor surfaces (fingers, knees, elbows)
- **Commonly affects** scalp, **nails** (“nail pitting”)
- Musculoskeletal examination consistent with arthritis
- **Asymmetric** involvement of both peripheral, axial joints
- **Commonly affects** DIP joints under skin manifestations



**Figure 111.9** An X-ray image of the hands of an individual with long-standing psoriatic arthritis which has progressed to arthritis mutilans. Telescoping of the phalangeal joints is visible.

## TREATMENT

### MEDICATIONS

#### Mild disease

- NSAIDs

#### Moderate-severe disease

- Conventional (DMARD) therapy
- Methotrexate (MTX; co-treat with daily folic acid), leflunomide (does not also target skin disease)
  - Both require eliminating alcohol intake

#### Severe disease

- ‘Biologic’ DMARD (e.g. TNF inhibitor)
- Etanercept, adalimumab, infliximab, certolizumab
  - All require latent TB screening before initiation therapy initiation
- Anti-IL-17 ‘biologic’ (e.g. secukinumab, ixekizumab, brodalumab)

### OTHER INTERVENTIONS

- Exercise, physical therapy, occupational therapy
- Weight reduction

# REACTIVE ARTHRITIS

osms.it/reactive-arthritis

## PATHOLOGY & CAUSES

- **Group:** seronegative spondyloarthritides
- Characterized by triad
  - Arthritis, nongonococcal urethritis/cervicitis, conjunctivitis
- AKA Reiter syndrome
- **Hypothesis:** autoimmune reaction to prior infection of GU/GI system
- **Genitourinary triggers:** urethritis/cervicitis
  - Common pathogen: *Chlamydia trachomatis*
- **Gastrointestinal triggers:** diarrheal illness
  - Common pathogens: *Shigella*, *Salmonella paratyphi*, *Yersinia enterocolitica*, *Campylobacter jejuni*
- RF
- HIV ⊕
- HLA-B27 ⊕ (80+% of affected individuals)

## COMPLICATIONS

- Digital tendon sheath synovitis → dactylitis (“sausage” finger/toe)
- Tendoligamentous insertion sites ossification → calcaneal spurs, bony outgrowths
- Severe spinal disease; becomes indistinguishable from ankylosing spondylitis
- Extra-articular involvement
  - Inflammatory balanitis, conjunctivitis, cardiac conduction abnormalities, aortic regurgitation

## SIGNS & SYMPTOMS

### Arthritic symptoms

- Develop several weeks post-initial infection
- Common, early symptoms
  - Joint stiffness, low back pain
- Days later
  - Painful joints, effusion, lack of mobility

- Most asymmetrically affected joints
  - Ankles, knees, feet; upper extremity involvement less common

### Other symptoms

- Fever, malaise, weight loss, fatigue
- Symptoms’ severity waxes, wanes; usually lasts 1.5–6 months
- Recurrent arthritic episodes, tendonitis, lumbosacral pain in 50% of individuals
- Keratoderma blennorrhagicum
  - Vesiculopustular, waxy lesions on the soles or palms



**Figure 111.10** Keratoderma blennorrhagicum on the feet of an individual with reactive arthritis.

## DIAGNOSIS

### DIAGNOSTIC IMAGING

#### X-ray

- Involved joint
  - No specific diagnostic changes
- Negative for stress fractures, other forms of arthritis

## LAB RESULTS

### Synovial fluid analysis

- Absence of joint space infection, crystals

### Cultures

- May be helpful if GI/GU symptoms ongoing → identify well-associated bacteria

## OTHER DIAGNOSTICS

### History

- Preceding illness, rapid-onset arthritis/systemic symptoms
- Arthritic presentation often too late for stool/urine culture (for GU/GI trigger)

### Physical examination

- Lower extremity joint involvement as above

## TREATMENT

### MEDICATIONS

- NSAIDs
- Glucocorticoids; intra-articular, systemic formulation available
- Resistant/chronic (> six months) disease
  - DMARD (e.g. sulfasalazine, MTX, azathioprine)
- Antibiotics not recommended
  - **Exception:** triggering disease process (GI/GU diarrhea/urethritis/cervicitis) ongoing
- Skin involvement (if present) → topical salicylates

### OTHER INTERVENTIONS

- Conjunctivitis (if present) → ophthalmology referral

# RHEUMATOID ARTHRITIS

[osms.it/rheumatoid-arthritis](https://osms.it/rheumatoid-arthritis)

## PATHOLOGY & CAUSES

- Systemic, chronic, **autoimmune** inflammatory disorder involving joint synovium
- May progress to disfigurement → cartilaginous, bony damage over time
- Dual hit hypothesis (genetics and environment)
  - **Genetics:** HLA-DR1 or DR4 genetic predisposition → thought to underlie the immune pathogenesis pathway below
  - **Environment:** cigarette smoke, pathogen (i.e. gut bacteria) → may contribute to unknown 'arthrogenic agent', trigger immune response

## PATHOLOGY

- **CD4<sup>+</sup> T cells:** react with arthrogenic agent (unknown; thought to be a microbe/self-antigen) → cytokine production → IFN-gamma (T<sub>H</sub>1 product) → activate macrophages and synovial cells → synovial, immune cell proliferation → swollen synovial tissue (also known as **pannus formation**) → IL-17 (T<sub>H</sub>17 product) → recruit neutrophils and monocytes → TNF-alpha and IL-1 (macrophage product) → stimulate synovial cells → protease release → hyaline **cartilage destruction** → ↓ cartilaginous buffer → bone on bone articulation → ↑ **bone destruction**
- **RANKL (on T cells):** activate osteoclasts' RANK receptor → bone resorption

- **Synovial cells:** directly responsible for protease release, contribution to cytokine milieu
  - Germinal centers within synovium include plasma cells → antibodies against self-antigens, i.e. autoantibodies → specific for citrullinated peptides (CCPs)/arginine residues converted to citrulline
  - Antibodies against fibrinogen, type II collagen, alpha-enolase, vimentin → form antibody-antigen complexes → deposit into joints
  - Antibodies (usually IgM or IgA) against Fc regions of IgG antibodies form RF → deposit into joints
- Chronic inflammation → angiogenesis → increase inflammatory cell response → further joint involvement

### Extra-articular involvement

- Pyogens (i.e. IL-1)
  - → Hypothalamus → fever
- Skeletal
  - Protein breakdown
- Skin
  - Macrophage and lymphocytes recruitment → cycle of activation/recruitment → cells around a central necrotic mass → rheumatoid nodules
- Blood vessels
  - ↑ cytokines and ↑ circulating immune cells → altered endothelial cells → ↑ atheromatous plaques formation
- Liver
  - Under chronic inflammation → ↑ hepcidin production → ↓ iron absorption → anemia
- Lung
  - ↑ fibroblasts → lung fibrosis (AKA Caplan syndrome) → ↓ gas exchange (+/- pleural effusion)

## COMPLICATIONS

### Autoimmune

- AA amyloidosis
- Sjögren syndrome
- Scleritis

### Cardiovascular

- ↑ Atheromatous formation → ↑ MI, CVA risk
- Pericarditis → ↑ pericardial effusion risk

### Hematologic

- Anemia
- Felty syndrome (RA, splenomegaly, neutropenia)

### Musculoskeletal

- Rheumatoid nodules
  - Can form in any body tissue
- Baker (popliteal) cyst formation

### Neurological

- Carpal tunnel syndrome
- Mononeuritis multiplex
- C1-C2 instability → ↑ risk of subluxation → spinal cord impingement risk → neurologic involvement
- Serious complication if unknown at time of intubation

### Pulmonary

- Pleuritis → ↑ risk of pleural effusion (characteristically ↓ glucose, ↓ complement)
- Interstitial lung disease
- Caplan syndrome

## SIGNS & SYMPTOMS

### Inflammatory polyarthritis

- Commonly symmetrically affects multiple (> five) joints
- First smaller joints - MCP, PIP, MTP
- Avoids DIP joint
- Chronic disease → ↑ larger joint involvement

### Joint characteristics

- Warm, red, and painful joints
- Morning stiffness (lasting > one hour)

### Malformation

- Ulnar deviation of MCP joints
- Boutonniere (buttonhole) malformation
- Swan neck



**Figure 111.11** Ulnar deviation of the fingers in an individual with rheumatoid arthritis.

### Extra-articular manifestations

- Common, systemic signs
  - Fever, fatigue, weight loss
- Rheumatoid nodules
  - Commonly arise on extensor surfaces
- More varied sequelae in severe and/or chronic disease

## DIAGNOSIS

### DIAGNOSTIC IMAGING

#### X-ray

- Soft tissue swelling
- Bony erosions
- ↓ Bone density
- Narrowed joint space (late finding)

### LAB RESULTS

- RF titers
  - High titers associated with more severe disease
  - Eventually present in 80% of affected individuals
- Anti-citrullinated peptide/protein antibodies (anti-CCP)
  - Sensitivity 50–75%; specificity > 90%
- ↑ ESR, ↑ CRP
- Normocytic anemia (anemia of chronic disease)


### OTHER DIAGNOSTICS

#### History

- Symptoms for > six weeks

#### Physical examination

- Inflammatory (warm, stiff, painful) arthritis of > three joints
- Characteristic malformations
  - Ulnar deviation, boutonniere (“buttonhole”) malformation, swan neck malformation



**Figure 111.12** An X-ray image of the hands of an individual with rheumatoid arthritis. There is destruction of the metacarpophalangeal joints, the carpometacarpal joints and the wrist.

## TREATMENT

### MEDICATIONS

- NSAIDs
- Short-term, low-dose glucocorticoid
- DMARD
  - Hallmark of RA treatment
  - Methotrexate (give with folic acid to ↓ side effects)
  - Others: leflunomide, hydroxychloroquine, sulfasalazine
- Biologic DMARDs
  - Adalimumab, etanercept (intercept), infliximab particularly effective (block TNF-alpha, which is thought to underlie most joint damage)


- Abatacept (suppresses T cells)
- Rituximab (suppresses B cells)
- Anakinra (blocks IL-1)
- Tocilizumab (blocks IL-6)

### SURGERY

- Only if medication fails
- Severe joint malformation
  - Synovectomy
- Severe malformation, disability
  - Joint replacement

### OTHER INTERVENTIONS

- Exercise to maintain range of motion and muscle strength



**Figure 111.13** A histological section of a rheumatoid nodule. There is granulomatous inflammation composed of central fibrinoid necrosis and palisading histiocytes.